Cargando…
Direct Mass Spectrometry-Based Detection and Antibody Sequencing of Monoclonal Gammopathy of Undetermined Significance from Patient Serum: A Case Study
[Image: see text] Monoclonal gammopathy of undetermined significance (MGUS) is a plasma cell disorder characterized by the presence of a predominant monoclonal antibody (i.e., M-protein) in serum, without clinical symptoms. Here we present a case study in which we detect MGUS by liquid-chromatograph...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476240/ https://www.ncbi.nlm.nih.gov/pubmed/37499263 http://dx.doi.org/10.1021/acs.jproteome.3c00330 |
_version_ | 1785100885095874560 |
---|---|
author | Peng, Weiwei den Boer, Maurits A. Tamara, Sem Mokiem, Nadia J. van der Lans, Sjors P. A. Bondt, Albert Schulte, Douwe Haas, Pieter-Jan Minnema, Monique C. Rooijakkers, Suzan H. M. van Zuilen, Arjan D. Heck, Albert J. R. Snijder, Joost |
author_facet | Peng, Weiwei den Boer, Maurits A. Tamara, Sem Mokiem, Nadia J. van der Lans, Sjors P. A. Bondt, Albert Schulte, Douwe Haas, Pieter-Jan Minnema, Monique C. Rooijakkers, Suzan H. M. van Zuilen, Arjan D. Heck, Albert J. R. Snijder, Joost |
author_sort | Peng, Weiwei |
collection | PubMed |
description | [Image: see text] Monoclonal gammopathy of undetermined significance (MGUS) is a plasma cell disorder characterized by the presence of a predominant monoclonal antibody (i.e., M-protein) in serum, without clinical symptoms. Here we present a case study in which we detect MGUS by liquid-chromatography coupled with mass spectrometry (LC-MS) profiling of IgG1 in human serum. We detected a Fab-glycosylated M-protein and determined the full heavy and light chain sequences by bottom-up proteomics techniques using multiple proteases, further validated by top-down LC-MS. Moreover, the composition and location of the Fab-glycan could be determined in CDR1 of the heavy chain. The outlined approach adds to an expanding mass spectrometry-based toolkit to characterize monoclonal gammopathies such as MGUS and multiple myeloma, with fine molecular detail. The ability to detect monoclonal gammopathies and determine M-protein sequences straight from blood samples by mass spectrometry provides new opportunities to understand the molecular mechanisms of such diseases. |
format | Online Article Text |
id | pubmed-10476240 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-104762402023-09-05 Direct Mass Spectrometry-Based Detection and Antibody Sequencing of Monoclonal Gammopathy of Undetermined Significance from Patient Serum: A Case Study Peng, Weiwei den Boer, Maurits A. Tamara, Sem Mokiem, Nadia J. van der Lans, Sjors P. A. Bondt, Albert Schulte, Douwe Haas, Pieter-Jan Minnema, Monique C. Rooijakkers, Suzan H. M. van Zuilen, Arjan D. Heck, Albert J. R. Snijder, Joost J Proteome Res [Image: see text] Monoclonal gammopathy of undetermined significance (MGUS) is a plasma cell disorder characterized by the presence of a predominant monoclonal antibody (i.e., M-protein) in serum, without clinical symptoms. Here we present a case study in which we detect MGUS by liquid-chromatography coupled with mass spectrometry (LC-MS) profiling of IgG1 in human serum. We detected a Fab-glycosylated M-protein and determined the full heavy and light chain sequences by bottom-up proteomics techniques using multiple proteases, further validated by top-down LC-MS. Moreover, the composition and location of the Fab-glycan could be determined in CDR1 of the heavy chain. The outlined approach adds to an expanding mass spectrometry-based toolkit to characterize monoclonal gammopathies such as MGUS and multiple myeloma, with fine molecular detail. The ability to detect monoclonal gammopathies and determine M-protein sequences straight from blood samples by mass spectrometry provides new opportunities to understand the molecular mechanisms of such diseases. American Chemical Society 2023-07-27 /pmc/articles/PMC10476240/ /pubmed/37499263 http://dx.doi.org/10.1021/acs.jproteome.3c00330 Text en © 2023 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Peng, Weiwei den Boer, Maurits A. Tamara, Sem Mokiem, Nadia J. van der Lans, Sjors P. A. Bondt, Albert Schulte, Douwe Haas, Pieter-Jan Minnema, Monique C. Rooijakkers, Suzan H. M. van Zuilen, Arjan D. Heck, Albert J. R. Snijder, Joost Direct Mass Spectrometry-Based Detection and Antibody Sequencing of Monoclonal Gammopathy of Undetermined Significance from Patient Serum: A Case Study |
title | Direct Mass Spectrometry-Based
Detection and Antibody
Sequencing of Monoclonal Gammopathy of Undetermined Significance from
Patient Serum: A Case Study |
title_full | Direct Mass Spectrometry-Based
Detection and Antibody
Sequencing of Monoclonal Gammopathy of Undetermined Significance from
Patient Serum: A Case Study |
title_fullStr | Direct Mass Spectrometry-Based
Detection and Antibody
Sequencing of Monoclonal Gammopathy of Undetermined Significance from
Patient Serum: A Case Study |
title_full_unstemmed | Direct Mass Spectrometry-Based
Detection and Antibody
Sequencing of Monoclonal Gammopathy of Undetermined Significance from
Patient Serum: A Case Study |
title_short | Direct Mass Spectrometry-Based
Detection and Antibody
Sequencing of Monoclonal Gammopathy of Undetermined Significance from
Patient Serum: A Case Study |
title_sort | direct mass spectrometry-based
detection and antibody
sequencing of monoclonal gammopathy of undetermined significance from
patient serum: a case study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476240/ https://www.ncbi.nlm.nih.gov/pubmed/37499263 http://dx.doi.org/10.1021/acs.jproteome.3c00330 |
work_keys_str_mv | AT pengweiwei directmassspectrometrybaseddetectionandantibodysequencingofmonoclonalgammopathyofundeterminedsignificancefrompatientserumacasestudy AT denboermauritsa directmassspectrometrybaseddetectionandantibodysequencingofmonoclonalgammopathyofundeterminedsignificancefrompatientserumacasestudy AT tamarasem directmassspectrometrybaseddetectionandantibodysequencingofmonoclonalgammopathyofundeterminedsignificancefrompatientserumacasestudy AT mokiemnadiaj directmassspectrometrybaseddetectionandantibodysequencingofmonoclonalgammopathyofundeterminedsignificancefrompatientserumacasestudy AT vanderlanssjorspa directmassspectrometrybaseddetectionandantibodysequencingofmonoclonalgammopathyofundeterminedsignificancefrompatientserumacasestudy AT bondtalbert directmassspectrometrybaseddetectionandantibodysequencingofmonoclonalgammopathyofundeterminedsignificancefrompatientserumacasestudy AT schultedouwe directmassspectrometrybaseddetectionandantibodysequencingofmonoclonalgammopathyofundeterminedsignificancefrompatientserumacasestudy AT haaspieterjan directmassspectrometrybaseddetectionandantibodysequencingofmonoclonalgammopathyofundeterminedsignificancefrompatientserumacasestudy AT minnemamoniquec directmassspectrometrybaseddetectionandantibodysequencingofmonoclonalgammopathyofundeterminedsignificancefrompatientserumacasestudy AT rooijakkerssuzanhm directmassspectrometrybaseddetectionandantibodysequencingofmonoclonalgammopathyofundeterminedsignificancefrompatientserumacasestudy AT vanzuilenarjand directmassspectrometrybaseddetectionandantibodysequencingofmonoclonalgammopathyofundeterminedsignificancefrompatientserumacasestudy AT heckalbertjr directmassspectrometrybaseddetectionandantibodysequencingofmonoclonalgammopathyofundeterminedsignificancefrompatientserumacasestudy AT snijderjoost directmassspectrometrybaseddetectionandantibodysequencingofmonoclonalgammopathyofundeterminedsignificancefrompatientserumacasestudy |